[REVISION HISTORY]
Myasthenia gravis research and treatment in Italy
1 recorded revision of this situation.
What changed
2026-10-27 14:49 UTC → 2026-10-27 17:50 UTC ·
added
removed
Myasthenia gravis research and treatment in Italy
Efforts to manage and understand Myasthenia gravis, a rare autoimmune disease causing muscle weakness, have progressed through various clinical initiatives in Italy. Initial efforts included the ‘Training Xperience’ project, a field training initiative involving three major neurological centers in Lombardy. This project focused on personalizing therapeutic pathways and integrating different treatment modalities into clinical practice. Building on these efforts, the Poema study was launched to gather real-world evidence on the disease. This prospective study evaluates the response to efgartigimod treatment while examining psychological well-being, autonomy, and quality of life. The research involves 40 reference centers across Italy and monitors 100 patients over a 12-month period, period. At the 56th Congress of the Italian Society of Neurology, new findings from a multicenter study involving 14 centers were presented by neurologist Nicasio Rini. The research indicates that zilucoplan, a complement inhibitor, effectively improves patients' clinical conditions and quality of life. The treatment has been associated with enrollment having reached its halfway point. a ‘progressive reduction in daily corticosteroid dosages’ and a ‘drastic decrease in hospitalizations and rescue therapies’.
Versions
- 2026-10-27 17:50 UTC Myasthenia gravis research and treatment in Italy
- 2026-10-27 14:49 UTC Myasthenia gravis research in Italy
Select a version to see what changed compared to the one before it.